Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.269
Neutral
RSI(14)
66.658
Neutral
STOCH(KDJ)(9,3,3)
47.728
Buy
ATR(14)
3.232
High Vlolatility
CCI(14)
1.438
Neutral
Williams %R
16.066
Overbought
TRIX(12,20)
0.276
Sell
StochRSI(14)
100.000
Buy
Johnson & Johnson
JNJ210.098USD
+3.558+1.72%
Market hours （ET）Quotes delayed by 15 min
505.54BMarket Cap
20.13P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Johnson & Johnson
Currency: USD Updated: 2025-12-10Key Insights
Johnson & Johnson's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 26/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 203.44.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Johnson & Johnson's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
28
analysts
Buy
Current Rating
203.437
Target Price
+0.90%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Johnson & Johnson Highlights
StrengthsRisks
Johnson & Johnson is an American multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange (NYSE:JNJ). Its common stock is part of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest corporations in the United States. In 2024, it was ranked 45th on the Forbes Global 2000 list. Johnson & Johnson employs approximately 138,000 individuals globally, led by its current chairman and CEO, Joaquin Duato.
Founded in 1886 by three brothers—Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson—the company initially focused on selling ready-to-use sterile surgical dressings. In 2023, the firm spun off its consumer healthcare business segment into a new publicly traded entity, Kenvue, allowing it to concentrate solely on the development and manufacturing of pharmaceutical prescription drugs and medical device technologies.
Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.
Industry Leader
The company's revenue leads the industry, with the latest annual revenue totaling USD 88.82B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 84.05%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 84.05%.
Fairly Valued
The company’s latest PE is 19.79, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.79B shares, increasing 0.00% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 59.18K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-10The current financial score of Johnson & Johnson is 7.47, ranking 111/159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 23.99B, representing a year-over-year increase of 6.77%, while its net profit experienced a year-over-year increase of 91.24%.
Score
Financials
7.96
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.63
Operational Efficiency
7.57
Growth Potential
6.73
Shareholder Returns
7.46
Johnson & Johnson's Company Valuation
Currency: USD Updated: 2025-12-10The current valuation score of Johnson & Johnson is 7.77, ranking 48/159 in the Pharmaceuticals industry. Its current P/E ratio is 19.79, which is 76.44% below the recent high of 34.92 and 52.18% above the recent low of 9.47.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 26/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-10The current earnings forecast score of Johnson & Johnson is 7.50, ranking 103/159 in the Pharmaceuticals industry. The average price target for Johnson & Johnson is 205.00, with a high of 230.00 and a low of 170.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
28
analysts
Buy
Current Rating
203.437
Target Price
+0.90%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Johnson & Johnson
JNJ
28
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-10The current price momentum score of Johnson & Johnson is 9.32, ranking 17/159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 211.88 and the support level at 197.14, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
202.506
Buy
MA10
204.310
Buy
MA20
202.523
Buy
MA50
194.720
Buy
MA100
184.836
Buy
MA200
170.854
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-10The current institutional shareholding score of Johnson & Johnson is 7.00, ranking 44/159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 74.44%, representing a quarter-over-quarter increase of 0.74%. The largest institutional shareholder is The Vanguard, holding a total of 235.57M shares, representing 9.78% of shares outstanding, with 0.98% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
Geode Capital Management, L.L.C.
JP Morgan Asset Management
State Farm Insurance Companies
Norges Bank Investment Management (NBIM)
Wellington Management Company, LLP
Morgan Stanley Smith Barney LLC
BlackRock Asset Management Ireland Limited
1
2
Risk Assessment
Currency: USD Updated: 2025-12-10The current risk assessment score of Johnson & Johnson is 9.95, ranking 1/159 in the Pharmaceuticals industry. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.34
VaR
+1.55%
240-Day Maximum Drawdown
+12.73%
240-Day Volatility
+20.44%
Return
Best Daily Return
60 days
+3.29%
120 days
+6.19%
5 years
+6.19%
Worst Daily Return
60 days
-1.77%
120 days
-1.77%
5 years
-7.59%
Sharpe Ratio
60 days
+4.20
120 days
+4.05
5 years
+0.56
Risk Assessment
Maximum Drawdown
240 days
+12.73%
3 years
+18.58%
5 years
+23.63%
Return-to-Drawdown Ratio
240 days
+3.27
3 years
+0.41
5 years
+0.27
Skewness
240 days
-0.60
3 years
+0.04
5 years
+0.11
Volatility
Realised Volatility
240 days
+20.44%
5 years
+17.71%
Standardised True Range
240 days
+1.37%
5 years
+1.22%
Downside Risk-Adjusted Return
120 days
+883.36%
240 days
+883.36%
Maximum Daily Upside Volatility
60 days
+12.18%
Maximum Daily Downside Volatility
60 days
+10.54%
Liquidity
Average Turnover Rate
60 days
+0.35%
120 days
+0.37%
5 years
--
Turnover Deviation
20 days
+7.54%
60 days
+7.26%
120 days
+14.42%
Peer Comparison
Pharmaceuticals
Johnson & Johnson
JNJ
8.09 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.87 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.73 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.71 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Biogen Inc
BIIB
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Johnson & Johnson?
The TradingKey Stock Score provides a comprehensive assessment of Johnson & Johnson based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Johnson & Johnson’s performance and outlook.
How do we generate the financial health score of Johnson & Johnson?
To generate the financial health score of Johnson & Johnson, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Johnson & Johnson's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Johnson & Johnson.
How do we generate the company valuation score of Johnson & Johnson?
To generate the company valuation score of Johnson & Johnson, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Johnson & Johnson’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Johnson & Johnson’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Johnson & Johnson.
How do we generate the earnings forecast score of Johnson & Johnson?
To calculate the earnings forecast score of Johnson & Johnson, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Johnson & Johnson’s future.
How do we generate the price momentum score of Johnson & Johnson?
When generating the price momentum score for Johnson & Johnson, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Johnson & Johnson’s prices. A higher score indicates a more stable short-term price trend for Johnson & Johnson.
How do we generate the institutional confidence score of Johnson & Johnson?
To generate the institutional confidence score of Johnson & Johnson, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Johnson & Johnson’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Johnson & Johnson.
How do we generate the risk management score of Johnson & Johnson?
To assess the risk management score of Johnson & Johnson, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Johnson & Johnson’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Johnson & Johnson.
